Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab Ozogamicin in Adult ALL With Positive MRD Before SCT
NCT03610438Phase 2Active, not recruiting
- Sponsor
- GIMEMA
- Start
- Oct 2019
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of inotuzumab ozogamicin in acute lymphoblastic leukemia (ALL) (2 cohorts), sponsored by GIMEMA. Primary endpoint: Number of patients obtaining a negative Minimal Residual Disease (MRD) at 2 years. Started Oct 2019; status: active, not recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03610438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03610438.